Showing 341 - 360 results of 2,684 for search '"the Netherlands"', query time: 0.06s Refine Results
  1. 341
  2. 342
  3. 343
  4. 344

    Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) by Lotte Haverman, Eelco Franz, Ka Yin Leung, Albert Jan Van Hoek, Hans Knoop, Cees C van den Wijngaard, Elizabeth N Mutubuki, Tessa van der Maaden, Albert Wong, Anna D Tulen, Siméon de Bruijn

    Published 2022-07-01
    “…Hence, in this study, we aim to determine the prevalence, severity, risk factors and impact on quality of life of persisting symptoms in the first year following acute SARS-CoV-2 infection.Methods and analysis The LongCOVID-study is both a prospective and retrospective cohort study being conducted in the Netherlands, with a one year follow-up. Participants aged 5 years and above, with self-reported positive or negative tests for SARS-CoV-2 will be included in the study. …”
    Get full text
    Article
  5. 345

    Can electronic monitoring with a digital smart spacer support personalised medication adherence and inhaler technique education in patients with asthma?: Protocol of the randomised... by Job F. M. van Boven, Boudewijn H.J. Dierick, Maria Achterbosch, Sandra Been-Buck, Titia Klemmeier, Susanne J. van de Hei, Paul Hagedoorn, Huib A.M. Kerstjens, Janwillem W.H. Kocks

    Published 2022-06-01
    “…Secondary outcomes are patient and healthcare provider satisfaction and exploratory clinical outcomes are adherence, inhaler technique, TAI score, FeNO, lung function, ACQ and WPAI.Ethics and dissemination Ethical approval was obtained from the RTPO in Leeuwarden, Netherlands (number: NL78361.099.21). Patients will provide written informed consent. …”
    Get full text
    Article
  6. 346
  7. 347
  8. 348
  9. 349

    Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre... by Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, Marlies L. van Bekkum, Joan B. Heijns, Birgit E.P.J. Vriens, Mandy M. van Rosmalen, Lonneke W. Kessels, Lisanne Hamming, Karin J. Beelen, Peter Nieboer, Susan M. van den Berg, Esther Oomen-de Hoop, Rhodé M. Bijlsma, Monique E.M.M. Bos

    Published 2025-02-01
    “…Methods: Adult patients at least 18 years old diagnosed with hormone receptor positive, HER2− receptor negative MBC with a performance status of 0 or 1 who have been treated with capecitabine in the metastatic setting and up to two other lines of chemotherapy, including a taxane, were enrolled in this single-arm, multicentre, phase 2 study in the Netherlands. The participants received trifluridine-tipiracil 35 mg/m2 orally twice a day on days 1–5 and days 8–12 during a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent. …”
    Get full text
    Article
  10. 350
  11. 351

    The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles by Michiel T.H.M. Henkens, Anne‐Mar vanOmmen, Sharon Remmelzwaal, Gideon B. Valstar, Ping Wang, Job A.J. Verdonschot, Mark R. Hazebroek, Leonard Hofstra, Vanessa P.M. vanEmpel, Joline W.J. Beulens, Hester M. denRuijter, Stephane R.B. Heymans

    Published 2022-06-01
    “…Methods and results Subjects referred to the Cardiology Centers of the Netherlands, location Utrecht, with non‐acute possibly cardiac‐related symptoms (such as dyspnoea or fatigue) were prospectively enrolled in the HELPFul cohort (N = 507) and were included in the current analysis. …”
    Get full text
    Article
  12. 352
  13. 353
  14. 354
  15. 355
  16. 356
  17. 357
  18. 358
  19. 359

    Turning green: the impact of changing to more eco-friendly respiratory healthcare – a carbon and cost analysis of Dutch prescription data by Evelyn A Brakema, johan Kooistra, Niels Chavannes, Paul Hagedoorn, Pieter ten Have, Peter van Hal, Iris Wichers, Pauline de Heer, Hans C Ossebaard

    Published 2022-06-01
    “…We estimated that this could be reduced by 70% which would lead to an annual reduction in greenhouse gas emission of 63 million kg.CO2 equivalents saving at best EUR 49.1 million per year.Conclusions In the Netherlands, substitution of pMDIs to NPIs for eligible patients is theoretically safe and in accordance with medical guidelines, while reducing greenhouse gas emission by 63 million kg.CO2 equivalents on average and saving at best EUR 49.1 million per year. …”
    Get full text
    Article
  20. 360